Last reviewed · How we verify
Dextenza Ophthalmic Insert
Dextenza is a corticosteroid-eluting ophthalmic insert that delivers dexamethasone directly to ocular tissues to reduce inflammation and pain following eye surgery.
Dextenza is a corticosteroid-eluting ophthalmic insert that delivers dexamethasone directly to ocular tissues to reduce inflammation and pain following eye surgery. Used for Post-operative inflammation and pain following ocular surgery, Corneal refractive surgery pain and inflammation.
At a glance
| Generic name | Dextenza Ophthalmic Insert |
|---|---|
| Also known as | DEXTENZA |
| Sponsor | Ocular Therapeutix, Inc. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Dextenza is a sustained-release insert placed in the canaliculus (tear drainage system) that provides prolonged local delivery of dexamethasone, a potent corticosteroid. The insert gradually releases the drug over several days, maintaining therapeutic concentrations in the anterior segment of the eye while minimizing systemic exposure. This localized delivery reduces post-operative inflammation, pain, and the need for frequent topical eye drops.
Approved indications
- Post-operative inflammation and pain following ocular surgery
- Corneal refractive surgery pain and inflammation
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
- Increased intraocular pressure
Key clinical trials
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (EARLY_PHASE1)
- In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (PHASE4)
- Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus (EARLY_PHASE1)
- Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextenza Ophthalmic Insert CI brief — competitive landscape report
- Dextenza Ophthalmic Insert updates RSS · CI watch RSS
- Ocular Therapeutix, Inc. portfolio CI